BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Antag Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Antag Therapeutics's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07724340-213@assetmemo.bio
DTSTAMP:20261121T010143Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:AT-7687: Phase 2 readout est. (NCT07724340)
DESCRIPTION:AT-7687\, phase 2\, Obesity.\nStudy: A Study to Assess the Effi
 cacy\, Safety and Tolerability of AT673 Co-administered With Semaglutide i
 n Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity\
 nEstimated primary completion: February 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/at-7687#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07724340
URL:https://assetmemo.bio/drug/at-7687#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
